Effect of metformin on bioactive lipid metabolism in insulin-resistant muscle

Piotr Zabielski¹², Marta Chacinska²³, Karol Charkiewicz²⁴, Marcin Baranowski², Jan Gorski² and Agnieszka U Blachnio-Zabielska²³
¹Department of Medical Biology, Medical University of Bialystok, Bialystok, Poland
²Department of Physiology, Medical University of Bialystok, Bialystok, Poland
³Department of Hygiene, Epidemiology and Metabolic Disorders, Medical University of Bialystok, Bialystok, Poland
⁴Department of Perinatology, Medical University of Bialystok, Bialystok, Poland

Abstract

Intramuscular accumulation of bioactive lipids leads to insulin resistance and type 2 diabetes (T2D). There is lack of consensus concerning which of the lipid mediators has the greatest impact on muscle insulin action in vivo. Our aim was to elucidate the effects of high-fat diet (HFD) and metformin (Met) on skeletal muscle bioactive lipid accumulation and insulin resistance (IR) in rats. We employed a [U-¹³C]palmitate isotope tracer and mass spectrometry to measure the content and fractional synthesis rate (FSR) of intramuscular long-chain acyl-CoA (LCACoA), diacylglycerols (DAG) and ceramide (Cer). Eight weeks of HFD-induced intramuscular accumulation of LCACoA, DAG and Cer accompanied by both systemic and skeletal muscle IR. Metformin treatment improved insulin sensitivity at both systemic and muscular level by the augmentation of Akt/PKB and AS160 phosphorylation and decreased the content of DAG and Cer and their respective FSR. Principal component analysis (PCA) of lipid variables revealed that altered skeletal muscle IR was associated with lipid species containing 18-carbon acyl-chain, especially with C18:0-Cer, C18:1-Cer, 18:0/18:2-DAG and 18:2/18:2-DAG, but not palmitate-derived lipids. It is concluded that the insulin-sensitizing action of metformin in skeletal muscle is associated with decreased 18-carbon acyl-chain-derived bioactive lipids.

Introduction

Consumption of high-fat diet (HFD) and obesity are associated with accumulation of intramuscular lipids, leading to insulin resistance (IR) and type 2 diabetes (T2D). The mechanism underlying the induction of IR is still incompletely understood. Skeletal muscle is responsible for 70–80% of whole body insulin-stimulated glucose uptake and plays an important role in lipid metabolism. In obese and type 2 diabetic subjects, plasma free fatty acids (FFA) are often elevated compared to lean, healthy individuals (Belfort et al. 2005). Increased fatty acid uptake was observed in skeletal muscle from subjects consuming HFD (Roepstorff et al. 2004), individuals with T2D (Bruce et al. 2003) and obese humans (Simoneau et al. 1999). After entering the cell, FA are activated to long-chain fatty acyl-CoA (LCACoA), which are channeled toward mitochondrial β-oxidation through conversion to long-chain acyl-carnitines (LCAC) or de novo synthesis of intramyocellular lipids (IMCL) (Jeukendrup 2002). It is suggested that excess of LCACoA leads to overload of mitochondrial oxidative capacity and accumulation of IMCLs. This mechanism is amplified by the accumulation of malonyl-CoA which inhibits the activity of carnitine

Key Words
- type 2 diabetes
- high-fat diet
- insulin resistance
- metformin
- ceramide
- diacylglycerol
- skeletal muscle

Correspondence should be addressed to A U Blachnio-Zabielska
Email agnieszka.blachnio@umb.edu.pl
palmitoyltransferase (CPT-1) and diverts LCACoA toward de novo synthesis of lipids. The increased intracellular FA uptake and decline in mitochondrial FA channeling likely contributes to accumulation of IMCL and induction of IR. Current data suggest that intramuscular LCACoAs, diacylglycerols (DAG) and ceramides (Cer) promote the onset on IR by inhibiting key proteins within the insulin signaling pathway (Fig. 1). There is an ongoing discussion about which molecular lipid species play the leading role in FA-induced skeletal muscle IR. Elevated LCACoAs and impaired insulin-stimulated glucose uptake have been reported in skeletal muscle of obese individuals (Hulver et al. 2003) and with consumption of HFD in skeletal muscle of rats (Ellis et al. 2000). The accumulation of intracellular DAG has been demonstrated in the insulin-resistant muscle of HFD rats (Schmitz-Peiffer et al. 1990) and Zucker rats (Turinsky et al. 1990), whereas Cer accumulation has been shown in the muscles of obese, insulin-resistant rats (Turinsky et al. 1990) and obese insulin-resistant humans (Adams et al. 2004). The accumulation of LCACoAs and DAGs may interfere with insulin signaling through the activation of certain serine/threonine PKC isoenzymes (Itani et al. 2002), whereas accumulation of Cer can inhibit the insulin signaling pathway via protein phosphatase 2A (PPA2)-mediated inhibition of Akt/PKB (Schmitz-Peiffer et al. 1999) (Fig. 1).

Currently, there is a shift in interest from total intramyocellular fat accumulation to bioactive lipid classes and individual lipid species in the pathophysiology of insulin resistance (Kitessa & Abeywardena 2016). It appears that the acyl-chain length of particular bioactive lipids is an important factor in their deleterious effects on insulin signaling. The use of stable isotope-labeled FA and mass spectrometry allows for establishing the fate of intracellular fatty acids and precise measurement of fractional synthesis rate (FSR) of particular lipid species derived from labeled FA. Intramuscular content of bioactive lipids depends on the balance between lipid synthesis and degradation. For example, Cer accumulation can originate from de novo synthesis or release from complex sphingolipids such as sphingomyelins, glucosyl and galactosyl ceramides. Conversely, reduction in intramuscular Cer can arise from its hydrolysis or incorporation into complex sphingolipids. The use of stable isotope tracers allows for the identification of particular mechanism. Increase in the label incorporation without change in lipid concentration suggests increased incorporation of the lipid into complex species, whereas its accumulation under decreased labeling points to the degradation of complex species. Therefore, the main goal of this study was to measure both the concentration and synthesis rate (FSR) of different palmitate-derived lipid intermediates (LCACoAs, LCACs, DAGs, Cers) together with the expression of associated enzymes and correlate lipid variables with skeletal muscle IR in HFD-fed rats. We used the well-defined experimental model of HFD-induced skeletal muscle IR in rat and employed commonly prescribed insulin sensitizer, metformin, to reverse diet-induced insulin resistance. As palmitate (a major plasma FA) is widely used in studies of lipid-induced IR and serves as crucial intermediate in Cer synthesis, we employed a stable isotope-labeled [U-13C]palmitate...
tracer. Together with ultra-high-performance liquid chromatography (UHPLC)–tandem mass spectrometry (MS/MS), we measured FSR of palmitate-derived bioactive lipids in dietary-induced IR. To the best of our knowledge, our work is the first to describe the FSR of 16:0-CoA, 16:0-AC, 16:0-Cer, 16:0/16:0-DAG and C16:0/C18:1-DAG in complex experimental setup. Moreover, by applying metformin in HFD-induced insulin-resistant rats, together with an ability of measuring FSR of palmitate-derived lipids, we were able to establish the impact of metformin on the accumulation and synthesis rate of particular lipid species.

Materials and methods

Animals and study design

All procedures were approved by the Institutional Animal Care and Use Committee of Medical University of Bialystok. The experiments were carried out on male Wistar rats (6 weeks of initial age, 150 g of initial body weight). Animals were divided into following groups: (1) Control, fed control diet for 8 weeks (Research Diets INC D12450B, 10% calories from fat) (n=8); (2) high-fat diet (HFD), fed high-fat diet for 8 weeks (Research Diets INC D12492, 60% calories from saturated fat) (n=8); (3) metformin-treated (HFD/Met) fed HFD for 8 weeks and treated with metformin by oral gavage (300 mg/kg), starting from 5th week of HFD feeding (n=8). One week before euthanasia, an oral glucose tolerance test (OGTT) was performed. After 3 days of recovery, animals were subjected to intraperitoneal insulin tolerance test (IPTT). On the last day of the study, the food was withdrawn at 06:00 h and animals were fasted for 6 h. The [U-13C]palmitate tracer was given for 2 h as primed continuous infusion (0.5 µmol bolus; 0.3 µmol/kg/h continuous) through catheter placed in lateral tail vain. During the last 30 min, insulin bolus (0.5 U/kg) was administrated intravenously to measure insulin-stimulated protein phosphorylation. The rats were anesthetized by intraperitoneal injection of pentobarbital at a dose of 80 mg/kg. Both soleus muscles were removed, placed on ice and cleaned of connective tissue and fat. Tissue was frozen in liquid nitrogen and stored at −80°C until analysis.

Tracer infusion

Albumin-bound [U-13C]palmitate (potassium salt, uniformly labeled, Sigma-Aldrich) was prepared as previously described (Guo et al. 1997). Plasma palmitate concentration and isotopic enrichment were measured according to Persson and coworkers (Persson et al. 2010). Isotope tracer infusion was performed according to Blachnio-Zabielska and coworkers (Blachnio-Zabielska et al. 2013). The infusion protocol resulted in stable isotopic enrichment of plasma palmitate during 2 h of tracer infusion (Supplementary Fig. 1A, see section on supplementary data given at the end of this article). The area under palmitate enrichment curve was identical in all experimental groups (Supplementary Fig. 1B). ‘Extended materials and methods’ section of the supplement contains detailed description of tracer preparation, infusion and calculation of lipid turnover and FSR.

Measurement of lipid concentration and enrichment

Plasma FFA concentration and isotopic enrichment were measured by LC/MS (SIM mode) according to Persson and coworkers (Persson et al. 2010). Malonyl-CoA, LCACoA content and isotopic enrichment were measured according to Blachnio-Zabielska and coworkers (Blachnio-Zabielska et al. 2011). LCAC concentration and isotopic enrichment ([13C16]-carnitine) were measured according to Sun and coworkers (Sun et al. 2006) with minor modification. The ceramide content and isotopic enrichment were measured according to Blachnio-Zabielska and coworkers (Blachnio-Zabielska et al. 2012). The content and isotopic enrichment of DAG were measured according to Blachnio-Zabielska and coworkers (Blachnio-Zabielska et al. 2013). All measurements of lipid concentration and enrichment were performed using an Agilent 1290 Infinity UHPLC/Agilent 6460 Triple Quad (Agilent). Detailed description of the methods is presented in ‘Extended materials and methods’ section of the supplement.

Protein and RNA isolation

Total RNA and protein were isolated from muscle samples using NucleoSpin RNA/Protein isolation kit (Macherey-Nagel, Bethlehem, PA, USA), according to procedure by Bahn and coworkers (Bahn et al. 2008). RNA and proteins were separated on NucleoSpin columns according to manufacturer guidelines.

Western blot

Following target proteins were quantified using primary antibodies: GLUT4, FABP, CD36, FATP1, CPT1, ACC, ACS, SPT, PAP2B, Akt, pAktSer473, pAktThr308, AS160,
AS160Thr642 and GAPDH. Values were normalized to GAPDH protein expression measured in parallel runs and expressed as fold changes over control group values. All chemicals and equipment used for immunoblotting were purchased from Bio-Rad.

RT-PCR

The RNA was reverse transcribed into cDNA using iScript cDNA Synthesis Kit (Bio-Rad) with oligo(dT)\textsubscript{18}. Specific primers for the ACC, ACS, CD36, CPT1, FABP, FATP1, GLUT4, SPT and GAPDH were designed using the Beacon Designer Software. The housekeeping gene GAPDH was used as the reference gene for quantification. Quantitative real-time PCR was performed with SYBR Green Supermix Kit (Bio-Rad) using a Bio-Rad Chromo4 system.

Acyl-coenzyme A synthetase (ACSs) activity

Acyl-coenzyme A synthetase (ACSs) activity was assayed in muscle microsomes according to method by de Jong and coworkers (de Jong et al. 2007), with the use of radiolabeled [9,10\textsuperscript{3}H(N)]-palmitate (American Radiolabeled Chemicals, Inc. Saint Louis, MO, USA). The ‘Extended materials and methods’ supplement contains methodology description for the isolation of muscle microsomes and ACS synthase activity assay.

Phosphatidate phosphatase 2 (PAP2) activity

Activity of PAP2 in skeletal muscle microsomes was measured according to Martin and coworkers (Martin et al. 1991), with the use of radiolabeled 1-a-dioleoyl [oleoyl-1\textsuperscript{14}C]-glycerol-3-phosphate (American Radiolabeled Chemicals). The method is described in ‘Extended materials and methods’ section of the supplement.

Oral glucose tolerance test (OGTT), insulin tolerance test (IPTT), plasma insulin and HOMA-IR

The OGTT and IPTT tests were performed 3 days apart during the final week of the experiment. The food was withdrawn at 06:00h, and animals were fasted for 6h. For OGTT, animals received oral gavage of glucose at a dose of 3g/kg. For IPTT, animals received intraperitoneal injection of insulin at dose of 0.75 U/kg body weight. Blood samples from tail vein were measured at given intervals by glucometer (AccuCheck, Roche). Plasma insulin was measured by ELISA (Rat/Mouse Insulin Millipore).

HOMA-IR index value was calculated according to Cacho and coworkers (Cacho et al. 2008).

Principal component analysis, correlation analysis and statistical significance estimation

Statistical significance between groups was determined using ANOVA with the Tukey honestly significant difference post-hoc test for unequal n-numbers. Significance level was set at $P<0.05$. PCA was performed using Statistica 10.0 software package as described earlier (Zabielski et al. 2014). To prevent an artificial increase in the PCA model strength, we excluded a majority of closely interdependent variables.

Results

Whole-body insulin sensitivity

HFD-fed animals developed IR, as evidenced by elevated fasting blood glucose (Supplementary Table 1), impaired glucose tolerance (Fig. 2A and B), reduced insulin responsiveness (Fig. 2C and D) and increased HOMA-IR index. Metformin normalized insulin-related parameters to control values.

Skeletal muscle insulin sensitivity

Induction of IR in HFD animals was accompanied by decreased insulin-stimulated Akt phosphorylation (at Ser475 and Thr308) and AS160 phosphorylation in skeletal muscle (Fig. 2E, F and G). Improvement of insulin sensitivity in HFD/Met group was associated with significantly increased phosphorylation of Akt and AS160, as compared to HFD animals ($P<0.05$). Expression of GLUT4 protein increased significantly in HFD/Met compared to all other groups (in all cases, $P<0.05$, Fig. 2H). There were no significant changes in Glut4 mRNA (data not shown).

Plasma FFA concentration, muscle expression of FA transporters, ACS activity, acyl-CoA content and FSR

HFD increased total plasma FFA content (Fig. 3A, Supplementary Table 2) and turnover rate (Supplementary Fig. 1C and D) compared to control ($P<0.05$ in all cases). Metformin treatment normalized above variables except for total plasma FA turnover, which was still higher than control. Both HFD-treated
groups displayed significant increase in mRNA and protein levels of all measured fatty acid transporters (Fig. 3B and C). In the case of HFD/Met animals, the protein content of CD36 and FATP1 was the highest among all experimental groups. Increased plasma FFA and muscle FA transporters lead to accumulation of intramuscular LCACoA's in HFD group (Fig. 3D). Metformin strongly reduced the total LCACoA's in muscle, as compared to control and HFD animals. All of the above changes in the content of acyl-CoA were connected mainly with 18-carbon chain-derived acyl-CoA (C18:0-, C18:1 and C18:2-CoA, Supplementary Table 3). Those species were responsible for more than 75% of the observed increase above control levels. Although LCACoA content varied significantly between experimental groups, the elevation in Acs mRNA (data not shown) and protein (Fig. 3E) were not significant. Enzymatic activity of ACS increased significantly in both HFD-treated groups (Fig. 3F). There was no significant variation in tissue C16:0-CoA enrichment or FSR between experimental groups (Supplementary Fig. 2A and B), which indicates complete isotopic equilibration of acyl-CoA pool during 2h of tracer infusion. This allowed for estimation of C16:0-CoA turnover rate, which significantly increased in HFD animals and returned to control values under metformin treatment (Supplementary Fig. 2C).

**Indicators of mitochondrial FA channeling**

Accumulation of LCACoA in muscle of HFD animals was accompanied by significantly decreased content and FSR of C16:0-AC (Fig. 4A, B and Supplementary Table 4) and Cpt1 mRNA expression (Fig. 4C). HFD significantly decreased C16:0-AC to C16:0-CoA ratio and respective FSR ratio (Fig. 4E and Supplementary Fig. 3), which suggest an inhibition of mitochondrial FA channeling. Metformin increased C16:0-AC content and FSR despite downregulation of CPT1 expression at both the mRNA and the protein level, as compared to control. Moreover, metformin increased C16:0-AC to C16:0-CoA ratio, and respective FSR ratios, which indicates augmentation of mitochondrial channeling of FA.

Muscle malonyl-CoA content doubled in HFD animals as compared to control (Fig. 4F). Although HFD decreased mRNA of Acc (Fig. 4G), the de-phosphorylation of ACC protein indicates its activation under HFD treatment (Fig. 4H). Metformin normalized ACC phosphorylation to control values and significantly decreased malonyl-CoA content.

**Muscle bioactive lipids**

HFD significantly increased muscle ceramide content (Fig. 5A), which was accompanied by the upregulation of
Bioactive lipids in insulin-resistant muscle

Figure 3
The effect of metformin on intracellular uptake and acyl-CoA conversion of fatty acids in in skeletal muscle of HFD-fed animals. Panel A – plasma FFA; B, C – protein and mRNA expression of Cd36, Fatp1 and Fabp pm. D – muscle acyl-CoA content; E and F – protein expression and enzymatic activity of ACS. Values are mean±s.d. (n=8 for each group), P<0.05 against: a- vs C; *- vs HFD.

Spt mRNA and protein level (Fig. 5C, D and Supplementary Table 5). Interestingly, increase in the total content of Cer in HFD animals was not associated with an increase in FSR of C16:0-Cer (Fig. 5B). The C18:0 and C18:1 ceramides had the greatest impact on the total content of ceramide in HFD group (Supplementary Table 5 and accompanied figures). Both the FSR and content of C16:0-Cer did not increase despite HFD treatment, which indicates selective synthesis of ceramide species (Supplementary Fig. 4). Metformin normalized the total content of ceramide as well as mRNA and protein expression of SPT and decreased the FSR of 16:0-Cer.

High-fat diet triggered modest yet significant accumulation of intramuscular DAG (Fig. 5E), with C18:0/C18:2- and C18:2/C18:2-DAG accounting for majority of change in total DAG (Supplementary Table 6 and accompanied figures). Interestingly, as compared to control, the content of palmitate-derived DAG remained unchanged (16:0/16:0-DAG) or even decreased (16:0/18:1- and 16:0/18:0-). The same could be noted for 16:0/16:0- and 16:0/18:1-DAG FSR (Supplementary Fig. 5). The mismatch between total content of DAG and FSR of palmitate-derived DAGs suggests selective synthesis of 18-carbon acyl-chain DAGs under HFD treatment. Accumulation of DAG was accompanied by increased activity and protein expression of PAP2 (Fig. 5G and H). Metformin treatment decreased the total content of DAG, the FSR of 16:0/16:0- and 16:0/18:1-DAG, and both the activity and protein level of PAP2 (P<0.05 vs HFD).

Principal component (PCA) analysis
Three major principal components were responsible for a total of 79% of cumulative variance within the data set (pc1=45.8%, pc2=27.2%, pc3=6%; cumulative R2X=0.790, Q2=0.674). Scores biplot shows separate, tight clustering of animals from each experimental group (Fig. 6A), with clear separation of HFD group along t2 axis. Overlay of variable vectors show that factors that differentiate HFD group from control and HFD/Met animals were mostly indicators of insulin resistance and sensitivity, 18-carbon acyl-chain length Cer, DAG and acyl-CoA (along t2 axis). Also, variables associated with lipid mitochondrial channeling and insulin signaling,
such as total acyl-carnitine content and FSR, acyl-carnitine to acyl-CoA ratio and Akt phosphorylation distinguished control and HFD/Met group from HFD animals. Surprisingly, some of the Cer and all palmitate-derived DAGs were associated with the control animals, suggesting that those lipid species are not involved in the

Figure 4
Metformin promotes mitochondrial channeling of fatty acids in skeletal muscle of HFD-fed animals. Panel A and B – total long-chain acyl-carnitine (LCAO) content and FSR; Panel C and D – mRNA and protein expression of CPT1. Panel E – 16:0-AC to 16:0-CoA ratio (a measure of mitochondrial fatty acids uptake); Panel F – malonyl-CoA content; Panels G and H – mRNA expression and protein phosphorylation of ACC. Values are mean ± s.d. (n = 8 for each group), P < 0.05 against: a- vs C; *- vs HFD.

Figure 5
Metformin inhibits synthesis of Cer and DAG in skeletal muscle of HFD-fed animals. Panels A and B – total ceramide content and C16:0-Cer FSR; Panels C and D mRNA and protein expression of SPT; Panels E and F – total DAG content 16:0/16:0-DAG FSR; Panels G and H – phosphatidic acid phosphatase 2 (PAP2) activity and protein expression. Values are mean ± s.d. (n = 8 for each group), P < 0.05 against: a- vs C; *- vs HFD.
It has been postulated that accumulation of these lipid intermediates induces defects in the insulin signaling cascade (Houmard et al. 2002, Bruce et al. 2006) and decreases insulin-stimulated glucose uptake (Hegarty et al. 2003). Metformin, a commonly used hypoglycemic drug, lowers blood glucose by decreasing hepatic glucose production and increasing glucose uptake by skeletal muscle. However, the relationship between insulin-sensitizing effects of metformin and bioactive lipids is not completely understood. Our study was designed to evaluate the involvement of particular lipid species in induction of IR and to evaluate the impact of metformin on muscle bioactive lipid metabolism. We employed a stable isotope-labeled palmitate tracer and MS-based methods to measure muscle concentration and synthesis rates of palmitate-derived lipids that are known inhibitors of insulin signaling pathway (LCACoA, DAG and Cer).

High rates of FA uptake into skeletal muscle may, at least in part, be responsible for IMCL accumulation. Previously, it has been shown that muscle of obese or T2D animals display increased rates of FA uptake (Luiken et al. 2001). Our results indicate that skeletal muscle IR in HFD animals is associated with increased content and turnover rate of plasma FFA and skeletal muscle LCACoA due to upregulation in FA transporters and ACS activity. LCACoA are oxidized in mitochondria or used in lipid de novo synthesis. In our study, we tried to answer the question of how HFD consumption affects LCACoA channeling and what is the impact of metformin on this process. Mitochondrial β-oxidation is dependent on activity of carnitine palmitoyltransferase 1 (CPT1) and intracellular level of CPT1 inhibitor malonyl-CoA (Drynan et al. 1996). Malonyl-CoA is synthesized from acetyl-CoA by the action of acetyl-CoA carboxylase (ACC) (McGarry et al. 1983). ACC is inhibited by AMPK-dependent phosphorylation. It has been found that skeletal muscle accumulates malonyl-CoA under hyperglycemia and hyperinsulinemia (Sidossis et al. 1999, Rasmussen et al. 2002), which are
associated with IR. It is suggested that the re-channeling of FA from oxidation to IMCL synthesis observed with IR may be attributable to high malonyl-CoA levels and high ACC activity. In our study, HFD consumption triggered accumulation of intramyocellular malonyl-CoA and activation of ACC, which was accompanied by decreased acyl-carnitine content, fractional synthesis rate and acyl-carnitine to acyl-CoA ratio. Our results indicate that in insulin-resistant muscle, there is a mismatch between fatty acid uptake and mitochondrial channeling, which leads to the accumulation of LCACoA. Metformin augmented mitochondrial channeling of FA as indicated by the decrease in content and turnover rate of plasma FFA and muscular LCACoA. Moreover, we observed a significant decline in malonyl-CoA and inhibition of ACC, accompanied by increased content and FSR of acyl-carnitine, acyl-carnitine/acyl-CoA ratio and their respective FSR ratio as compared to HFD group. All observed changes suggest increased mitochondrial channeling of LCACoA under metformin treatment, which shifts fatty acids flux from IMCL synthesis toward β-oxidation.

HFD feeding led to the accumulation of muscular ceramide. However, not all Cer species were affected equally. Accumulation was most pronounced for C18:0-Cer and C18:1-Cer. Interestingly, content and FSR of C16:0-Cer was not higher than control, suggesting selective synthesis of Cer species in skeletal muscle under HFD feeding. Although accumulation of C16:0-Cer was previously associated with hepatic insulin resistance (Raichur et al. 2014, Turpin et al. 2014), there is a growing body of evidence that 18-carbon fatty acyl-chain ceramides associate with skeletal muscle IR. Those Cer species are responsible for majority of Cer accumulation in skeletal muscle of HFD-fed animals (Lanza et al. 2013), mice with uncontrolled STZ-diabetes (Zabielski et al. 2014) as well as in obese, type 2 diabetic patients (Bergman et al. 2016). Selective Cer synthesis also explains the mismatch between total ceramide accumulation and C16:0-Cer FSR observed in our study. We infused labeled palmitate to track synthesis of Cer, whereas stearoyl and oleoyl ceramides were used to determine the total content of intramuscular Cer. The improvement of skeletal muscle insulin sensitivity under metformin treatment was also associated with reduced 18-carbon FA-derived ceramides, whereas other ceramide species remained unaffected. The importance of those Cer species in HFD-induced skeletal muscle IR is further supported by the results of PCA analysis, which show close association of stearoyl- and oleoyl-Cer with the HFD group and the measures of muscular IR. Muscle DAG accumulation was evident in insulin resistance states and obesity (Turinsky et al. 1990, Oakes et al. 1994, Schmitz-Peiffer et al. 1997). Our data indicate that 18-carbon acyl-chain length DAGs account for majority of the increase in total DAG under HFD treatment. Among diacylglycerol species, 18:0/18:2- and 18:2/18:2-DAG displayed the strongest variation in content with both induction of muscular IR and improvement of IR under metformin treatment. In the study by Szendroedi and coworkers, those particular DAG species displayed the strongest negative correlation with glucose disposal rate and positive correlation with PKC-0 activation in insulin-resistant muscle of obese or T2D diabetic subjects (Szendroedi et al. 2014). Insulin resistance induced by lipid infusion in sedentary subjects is also connected with oleoyl-, linoloyl- and linoleoyl-DAG accumulation in skeletal muscle (Chow et al. 2014). Our findings indicate that 18-carbon acyl-chain DAGs are associated with the induction of skeletal muscle IR. Interestingly, the palmitate-derived DAGs do not accumulate in IR muscle due to decreased FSR, which suggests less impact of those DAG species on muscular insulin sensitivity. Although the results of FSR measurement of palmitate-derived lipids indicate selective synthesis of intramuscular lipid species, the definitive confirmation requires the use of multiple fatty acids tracers. The drawback of our study was the use of single-tracer approach. Although it allowed us for differentiation between palmitate-derived and other lipid species, we could not measure FSR of stearate-derived lipids. Stearate-derived lipids had the greatest impact on total intramuscular lipid content in each of the measured lipid classes, and future studies must include additional fatty acids tracers, which reflect the lipid composition of the tissues of interest. At the molecular level, DAGs stimulate serine/threonine kinases, which inhibit IRS-1 activation due to phosphorylation of other than tyrosine amino acid residues (Itani et al. 2002). Ceramide activates PP2A phosphatase, which decreases Akt phosphorylation (Adams et al. 2004, Hsieh et al. 2014). Both mechanisms lead to the inhibition of insulin signaling cascade, decrease in AS160 phosphorylation, GLUT4 translocation, reduction of glucose uptake and induction of IR (Turinsky et al. 1990, Adams et al. 2004, Holland et al. 2007). Previous studies showed that metformin increased glucose uptake in cultured human muscle cells (Sarabia et al. 1992) or muscle strips from diabetic subjects (Galuska et al. 1991) and prevents IR (Holland et al. 2007, Usher et al. 2010); yet, there was no compelling evidence of involvement of particular lipid species in the processes. Our results indicate that decreased 18-carbon
acyl-chain-derived bioactive lipids (both Cer and DAG) is strongly associated with insulin-sensitizing effects of metformin and augmentation of both the Akt and AS160 phosphorylation in skeletal muscle of HFD-treated animals. Yet, it should be noted that total content and 18-carbon acyl-chain-derived Cer, as compared to similar DAG species, demonstrate the strongest association with induction and reduction of insulin resistance.

Taking together, on the one hand, HFD consumption increases plasma concentration of FFA, and on the other hand, impairs mitochondrial channeling of FA in skeletal muscle through malonyl-CoA-mediated inhibition of CPT1. As a result, we have observed an accumulation of LCACoA, DAGs and Cers, which was most notable for lipid species acylated with 18-carbon chain length fatty acids. These changes were accompanied by decreased phosphorylation of Akt (Ser473 and Thr308) and AS160 and impaired whole body glucose disposal. Metformin treatment augmented mitochondrial channeling of FA by the reduction of CPT1 inhibition by malonyl-CoA and decreased 18-carbon acyl-chain-derived bioactive lipids. Our results indicate that accumulation of bioactive lipids acylated with stearoyl and oleoyl and linoleoyl fatty acids plays a major role in the induction of skeletal insulin resistance.

Supplementary data
This is linked to the online version of the paper at http://dx.doi.org/10.1530/JOE-16-0381.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding
This work was supported by Foundation for Polish Science Grant HOMING PLUS/2010-2/1 and by the Medical University of Białystok (Grants 143-18558, 143-18559 and 143-18726).

Author contribution statement
A B Z conceived and designed the study; P Z and M C performed animal experiments and ACS activity measurements; A B Z performed all lipid-related measurements; A B Z performed gene expression measurements; P Z and K C performed WBB analysis; M B performed hormone measurements; P Z performed statistical and PCA analysis of the data; A B Z and P Z analyzed data and interpreted results of the experiments; A B Z and P Z prepared figures and drafted the manuscript; A B Z and J G edited and revised the manuscript and A B Z coordinated and directed the project.

Acknowledgements
The authors thank Dr Ian Lanza (Mayo Clinic, Rochester, MN, USA) for his support in improving the final draft of the manuscript.

References
Bioactive lipids in insulin-resistant muscle


Schmitz-Peifer C, Craig DL & Biden TJ 1999 Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate. *Journal of Biological Chemistry* **274** 24202–24210. (doi:10.1074/jbc.274.34.24202)


Received in final form 14 March 2017

Accepted 11 April 2017